CD86 and hepatocellular carcinoma: By directly regulating downstream cell cycle regulators (cyclin D1 and E2F1) 18, 19 and immune checkpoint regulators (IDOs, PD‐L1, and B7‐2) 17, ISX has been shown to promote cell tumorigenic activities and is highly correlated with patient poor prognosis, highlighting its importance in regulating HCC progression 18.